Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Methods in Molecular Medicine|February 23, 2011
Use of diphenylamine in the detection of apoptosisR K Gibb, C Gercel-Taylor
International Journal of Oncology|February 20, 1999
Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroidsS Makhija, D D Taylor, R K Gibb, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|December 31, 1997
Lymphokine-activated killer (LAK)-mediated lysis of sequentially isolated ovarian cancer cell linesC M Yashar, D D Taylor, R K Gibb, et al.
Annals of Diagnostic Pathology|December 10, 1998
Endometrial stromal sarcoma involving the placentaW A Katsanis, D M O'Connor, R K Gibb, et al.
Journal of the Society for Gynecologic Investigation|November 24, 1998
Inhibition of endometrial cancer cell lines by mifepristone (RU 486)C C Schneider, R K Gibb, D D Taylor, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|June 30, 1998
Identification of a unique form of p53 in human cord blood associated with the development of maternal autoantibodiesC M Yashar, C Gerçel-Taylor, R K Gibb, et al.
Gynecologic Oncology|April 1, 1997
Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell linesR K Gibb, D D Taylor, T Wan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2006
Increased risk for abnormalities on perioperative colon screening in patients with microsatellite instability-positive endometrial carcinomaB M Buttin, M A Powell, P J Goodfellow, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2008
Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancerT T Nguyen, J D Wright, M A Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2007
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerJ D Wright, A A Secord, T M Numnum, et al.
Pageof 1